Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-PSMA-1007 PET/CT in Prostate Cancer
NCT06723665Enrolling by invitation
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of radelumin in prostate cancer (PCa) (2 arms), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoint: Comparison of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT imaging advantages at 1 day. Started Jan 2024; status: enrolling by invitation.
02
Drugs
radelumin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06723665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06723665.